A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Clinical trial NCT03394365 · RECRUITING

Trial details

NCT number: NCT03394365
Sponsor: Pierre Fabre Medicament
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant Complications Lymphoproliferative Disorders Allogeneic Hematopoietic Cell Transplant Stem Cell Transplant Complications

Start date: 2017-12-29
Primary completion: 2030-05-31
Enrollment: 115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.